Rhythm Pharmaceuticals Stock Price

0.51 (6.99%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 444,991
Bid Price 7.27
Ask Price 10.16
News -
Day High 7.88


52 Week Range


Day Low 6.89
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Rhythm Pharmaceuticals Inc RYTM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.51 6.99% 7.81 18:00:07
Open Price Low Price High Price Close Price Prev Close
7.04 6.89 7.88 7.81 7.30
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,016 444,991 $ 7.38 $ 3,286,169 - 6.89 - 43.26
Last Trade Time Type Quantity Stock Price Currency
19:35:04 1 $ 7.82 USD


Draw Mode:

Rhythm Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 392.60M 50.27M 38.73M $ - $ - -3.05 -5.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 1.80%

more financials information »

Rhythm Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RYTM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week9.3459.3456.897.70279,210-1.54-16.43%
1 Month12.2012.366.899.52318,511-4.39-35.98%
3 Months11.5514.216.8910.47352,131-3.74-32.38%
6 Months19.8920.216.8911.86324,863-12.08-60.73%
1 Year39.7143.266.8918.90371,927-31.90-80.33%
3 Years28.7743.266.8921.35281,197-20.96-72.85%
5 Years23.2143.266.8923.05254,901-15.40-66.35%

Rhythm Pharmaceuticals Description

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.

Your Recent History
Rhythm Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.